• PDF / 169,218 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 27 Downloads / 163 Views

DOWNLOAD

REPORT

---

1 S

Neuropathy: case report In a retrospective descriptive study (between January 2014 and December 2017) of 50 patients, a patient [age and sex not stated] was described, who developed neuropathy during treatment with gemcitabine and paclitaxel for pancreatic adenocarcinoma. The patient, who had pancreatic adenocarcinoma, started receiving paclitaxel [nab-paclitaxel] 125 mg/m2 followed by gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 4 weeks [routes not stated]. However, the patient developed grade III neuropathy secondary to gemcitabine and paclitaxel [time to reaction onset not stated]. Hence, the patient’s therapy with gemcitabine and paclitaxel was discontinued after 2 months of treatment [outcome not stated]. Nebot-Villacampa MJ, et al. Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma. Journal of Oncology 803504746 Pharmacy Practice 26: 603-611, No. 3, Apr 2020. Available from: URL: http://doi.org/10.1177/1078155219862035

0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 3 Oct 2020 No. 1824